Cargando…

Abaloparatide Real‐World Patient Experience Study

Despite the availability of various osteoporosis treatments, adherence remains suboptimal. One contributing factor may be patient experience with therapy. This US, multicenter, combined retrospective chart review and patient questionnaire study included postmenopausal women at high risk for fracture...

Descripción completa

Detalles Bibliográficos
Autores principales: Gold, Deborah T, Weiss, Richard, Beckett, Tammy, Deal, Chad, Epstein, Robert S, James, Andrew L, Kernaghan, Jacqueline M, Mohseni, Mahshid, Spiegel, Michael, Vokes, Tamara, Roberts, Jenna, Bailey, Tom, Wang, Yamei, Williams, Setareh A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990148/
https://www.ncbi.nlm.nih.gov/pubmed/33778325
http://dx.doi.org/10.1002/jbm4.10457
_version_ 1783669021947723776
author Gold, Deborah T
Weiss, Richard
Beckett, Tammy
Deal, Chad
Epstein, Robert S
James, Andrew L
Kernaghan, Jacqueline M
Mohseni, Mahshid
Spiegel, Michael
Vokes, Tamara
Roberts, Jenna
Bailey, Tom
Wang, Yamei
Williams, Setareh A
author_facet Gold, Deborah T
Weiss, Richard
Beckett, Tammy
Deal, Chad
Epstein, Robert S
James, Andrew L
Kernaghan, Jacqueline M
Mohseni, Mahshid
Spiegel, Michael
Vokes, Tamara
Roberts, Jenna
Bailey, Tom
Wang, Yamei
Williams, Setareh A
author_sort Gold, Deborah T
collection PubMed
description Despite the availability of various osteoporosis treatments, adherence remains suboptimal. One contributing factor may be patient experience with therapy. This US, multicenter, combined retrospective chart review and patient questionnaire study included postmenopausal women at high risk for fracture and is the first study to describe real‐world patient experience with abaloparatide (ABL) injection. Eight geographically diverse secondary care sites in the United States participated (n = 193). Mean ± SD age was 67.4 ±8.62 years. Most patients (86%) were satisfied with the ABL regimen, especially with ease of preparation (82%), ease of storage (87%), and storage convenience (89%), an attribute 83% of the patients thought was important. The majority of patients reported complete satisfaction with the ABL regimen allowing for their ability to conduct daily activities (85%) and convenience to fit into their daily schedule (84%). All reported taking ABL as directed, by injection in the lower abdomen, and 83% of patients reported medium or high adherence. Patients were satisfied with the needle size (76% completely satisfied), and 93% reported never deliberately missing a dose. Although injecting medication (18%) and higher out‐of‐pocket costs (17%) were deemed the most bothersome attributes, the majority (69%) noted their healthcare team understands how osteoporosis impacts their lives. In multivariable analyses, ease of preparation (OR = 2.62; 95% CI, 1.01–6.81; p = 0.048) and fracture history (OR = 1.72; 95% CI, 1.03–2.86; p = 0.037) were significantly associated with overall satisfaction. Ease of preparation was a predictor of higher satisfaction with treatment convenience (coefficient = 13.60; 95% CI, 8.08–19.12; p = 0.00). Remembering to take the medication was a significant predictor of self‐reported adherence (OR = 16.66; 95% CI, 3.30–84.24; p = 0.001). In conclusion, the majority of patients were satisfied with ABL and found it convenient/easy to prepare and store. High self‐reported adherence may be associated with positive patient experience including ease of use and adequate support from healthcare providers. © 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research.
format Online
Article
Text
id pubmed-7990148
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-79901482021-03-25 Abaloparatide Real‐World Patient Experience Study Gold, Deborah T Weiss, Richard Beckett, Tammy Deal, Chad Epstein, Robert S James, Andrew L Kernaghan, Jacqueline M Mohseni, Mahshid Spiegel, Michael Vokes, Tamara Roberts, Jenna Bailey, Tom Wang, Yamei Williams, Setareh A JBMR Plus Original Articles Despite the availability of various osteoporosis treatments, adherence remains suboptimal. One contributing factor may be patient experience with therapy. This US, multicenter, combined retrospective chart review and patient questionnaire study included postmenopausal women at high risk for fracture and is the first study to describe real‐world patient experience with abaloparatide (ABL) injection. Eight geographically diverse secondary care sites in the United States participated (n = 193). Mean ± SD age was 67.4 ±8.62 years. Most patients (86%) were satisfied with the ABL regimen, especially with ease of preparation (82%), ease of storage (87%), and storage convenience (89%), an attribute 83% of the patients thought was important. The majority of patients reported complete satisfaction with the ABL regimen allowing for their ability to conduct daily activities (85%) and convenience to fit into their daily schedule (84%). All reported taking ABL as directed, by injection in the lower abdomen, and 83% of patients reported medium or high adherence. Patients were satisfied with the needle size (76% completely satisfied), and 93% reported never deliberately missing a dose. Although injecting medication (18%) and higher out‐of‐pocket costs (17%) were deemed the most bothersome attributes, the majority (69%) noted their healthcare team understands how osteoporosis impacts their lives. In multivariable analyses, ease of preparation (OR = 2.62; 95% CI, 1.01–6.81; p = 0.048) and fracture history (OR = 1.72; 95% CI, 1.03–2.86; p = 0.037) were significantly associated with overall satisfaction. Ease of preparation was a predictor of higher satisfaction with treatment convenience (coefficient = 13.60; 95% CI, 8.08–19.12; p = 0.00). Remembering to take the medication was a significant predictor of self‐reported adherence (OR = 16.66; 95% CI, 3.30–84.24; p = 0.001). In conclusion, the majority of patients were satisfied with ABL and found it convenient/easy to prepare and store. High self‐reported adherence may be associated with positive patient experience including ease of use and adequate support from healthcare providers. © 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research. John Wiley & Sons, Inc. 2021-02-04 /pmc/articles/PMC7990148/ /pubmed/33778325 http://dx.doi.org/10.1002/jbm4.10457 Text en © 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Gold, Deborah T
Weiss, Richard
Beckett, Tammy
Deal, Chad
Epstein, Robert S
James, Andrew L
Kernaghan, Jacqueline M
Mohseni, Mahshid
Spiegel, Michael
Vokes, Tamara
Roberts, Jenna
Bailey, Tom
Wang, Yamei
Williams, Setareh A
Abaloparatide Real‐World Patient Experience Study
title Abaloparatide Real‐World Patient Experience Study
title_full Abaloparatide Real‐World Patient Experience Study
title_fullStr Abaloparatide Real‐World Patient Experience Study
title_full_unstemmed Abaloparatide Real‐World Patient Experience Study
title_short Abaloparatide Real‐World Patient Experience Study
title_sort abaloparatide real‐world patient experience study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990148/
https://www.ncbi.nlm.nih.gov/pubmed/33778325
http://dx.doi.org/10.1002/jbm4.10457
work_keys_str_mv AT golddeboraht abaloparatiderealworldpatientexperiencestudy
AT weissrichard abaloparatiderealworldpatientexperiencestudy
AT becketttammy abaloparatiderealworldpatientexperiencestudy
AT dealchad abaloparatiderealworldpatientexperiencestudy
AT epsteinroberts abaloparatiderealworldpatientexperiencestudy
AT jamesandrewl abaloparatiderealworldpatientexperiencestudy
AT kernaghanjacquelinem abaloparatiderealworldpatientexperiencestudy
AT mohsenimahshid abaloparatiderealworldpatientexperiencestudy
AT spiegelmichael abaloparatiderealworldpatientexperiencestudy
AT vokestamara abaloparatiderealworldpatientexperiencestudy
AT robertsjenna abaloparatiderealworldpatientexperiencestudy
AT baileytom abaloparatiderealworldpatientexperiencestudy
AT wangyamei abaloparatiderealworldpatientexperiencestudy
AT williamssetareha abaloparatiderealworldpatientexperiencestudy